{ }
The artificial intelligence in the diagnostic market is projected to grow from USD 1.1 billion in 2023 at a CAGR of 22.2% through 2032, driven by the rising prevalence of chronic diseases and the demand for AI tools in diagnostics. Key advancements include deep learning algorithms and natural language processing, enhancing diagnostic accuracy and operational efficiency across various medical applications, particularly in radiology, which accounted for 28.4% of market revenue in 2023. The market encompasses software, services, and hardware, with software being the primary revenue generator, reflecting the critical role of AI in transforming healthcare diagnostics.
The electronic skin patch market is rapidly expanding, driven by innovations in healthcare technology and increasing demand for continuous monitoring tools, particularly for diabetes management. Key players like Abbott and Dexcom, Inc. dominate the market, leveraging advanced glucose monitoring systems. The online segment is the fastest-growing, fueled by e-commerce adoption and telemedicine trends, while North America leads in market share due to its robust healthcare infrastructure.
Intelsat and Softbank are advancing toward a universal 5G broadband terminal that integrates satellite and terrestrial communications for global connectivity. This initiative follows the approval of Ku-band satellite spectrum for 5G standards and aims to provide seamless service across various markets, including automotive and military. While full standardization may take a few years, Intelsat hints at potential hybrid solutions that could be deployed as early as next year.
MINISO (MNSO) experienced a 6.4% rise in pre-market trading, reaching $16.13, following a "buy" rating from UBS. The firm highlighted the long-term appeal of popular intellectual properties, noting MINISO's successful product launches, including Chiikawa and Harry Potter, which are expected to boost customer loyalty. UBS set a target price of $26.5 for MINISO's U.S. stock, anticipating a 2025 price-to-earnings ratio of 18.
The global Metaverse in Healthcare market, valued at $6.57 billion in 2022, is projected to reach $71.65 billion by 2030, growing at a CAGR of 35.4%. Key drivers include the rising adoption of mixed reality in surgeries and medical training, alongside significant investments in digital healthcare platforms. North America leads the market, facing challenges such as data privacy concerns and high costs of advanced technologies.
The SMI closed lower, with Swiss Re among the decliners, while Wall Street showed weakness. In Tokyo, the Nikkei index rose 0.3% to 39,110.95, buoyed by technology stocks like Advantest and Tokyo Electron, despite caution ahead of corporate results and the upcoming general election on October 27. Fast Retailing, KDDI, and Daiichi Sankyo were among the notable losers.
US indices are set for historic gains, with the S&P 500 and Dow Jones on track for their best run since late 2023. The ASX 200 reached a record high, driven by strong bank performance, while key economic indicators showed positive trends in retail sales and job growth.Looking ahead, significant events include the Reserve Bank of Australia's speech and the release of various PMIs in the US, Europe, and Japan, alongside the third-quarter earnings season featuring major companies like Tesla and Boeing.
IG
The global Healthcare Fraud Analytics market, valued at $4.0 billion in 2023, is projected to reach $17.7 billion by 2030, growing at a CAGR of 23.6%. Key drivers include rising healthcare fraud, regulatory pressures, and advancements in AI and machine learning, enhancing fraud detection capabilities. The market is increasingly adopting cloud-based solutions for their scalability and cost-effectiveness, with significant growth expected in both descriptive and predictive analytics segments.
Abbott Laboratories, a leader in pharmaceutical and medical product development, has received a Buy rating from UBS. The company's net sales are primarily derived from diagnostic systems (39.1%) and vascular devices (24.7%), with significant contributions from nutritional products (12.1%) and medical products (8.2%). Geographically, the United States accounts for 38.5% of sales, followed by Germany (5.8%) and China (5.6%).

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.